StockNews.com Begins Coverage on Enzo Biochem (NYSE:ENZ)

Stock analysts at StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the medical research company’s stock.

Enzo Biochem Stock Performance

NYSE:ENZ opened at $0.43 on Monday. The firm has a 50-day simple moving average of $0.53 and a two-hundred day simple moving average of $0.83. Enzo Biochem has a fifty-two week low of $0.41 and a fifty-two week high of $1.30.

Enzo Biochem (NYSE:ENZ) last issued its earnings results on Monday, March 17th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter. The company had revenue of $7.33 million during the quarter. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%.

Institutional Trading of Enzo Biochem

A number of hedge funds and other institutional investors have recently modified their holdings of ENZ. Virtu Financial LLC purchased a new position in shares of Enzo Biochem during the 4th quarter valued at $35,000. Lepercq Multi Asset Fund purchased a new position in shares of Enzo Biochem in the fourth quarter valued at about $88,000. Wittenberg Investment Management Inc. lifted its position in shares of Enzo Biochem by 60.1% in the fourth quarter. Wittenberg Investment Management Inc. now owns 187,537 shares of the medical research company’s stock valued at $134,000 after acquiring an additional 70,400 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Enzo Biochem by 3.3% in the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after acquiring an additional 11,742 shares during the period. Finally, Mink Brook Asset Management LLC purchased a new stake in shares of Enzo Biochem during the fourth quarter worth about $577,000. 36.90% of the stock is owned by hedge funds and other institutional investors.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.